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Transdermal ^-Blocker Therapy in Essential 
Hypertension 
Claus Spieker, Hans Vetter, Rainer Lietke, Walter Ziek, an Wilhelm Vetter 
Transdermal drug delivery has been applied to various 
agents in an effort to decrease the frequency of drug 
administration and increase the patients compliance. In 
our study, we demonstrated that transdermal application 
of a ß-blocker (20 mg mepindolol) in patients with 
essential hypertension led to effective blood pressure 
lowering effect within 1 week (160.1 ±6.1 mm Hg/95.8 ± 
8.3 mm Hg vs 136.8 ± 7.2 mm Hg/84.3 ± 5.0 mm Hg; 
Ρ < 0.05). A controlled study of transdermal versus oral 
ß-blocker administration in hypertensives is necessary 
before this new therapeutic system is introduced in 
antihypertensive treatment. Am J Hypertens 1988; 
1:199S-200S 
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Arecent important advance in drug administra­tion has been the controlled delivery of drugs to the systemic circulation through the intact skin. Current technology makes transdermal 
therapeutic systems of reasonable size practical for any 
given drug with low molecular weight, high lipid solu­
bility, and good effectiveness at a reasonable daily par­
enteral dosage. Up to now transdermal therapeutic sys­
tems with nitroglycerine or scopolamine and Clonidine 
have been successfully used in the treatment of angina 
pectoris, motoric sickness, or hypertension. 1 - 4 
Furthermore, the experience with the usage of trans­
dermal therapeutic systems does suggest the following 
advantages: (a) first-pass metabolism is avoided, (b) 
lower daily dosage because of continuous drug input 
and reduced liver metabolism, (c) fewer adverse effects 
due to lower dosages, (d) an improvement of the pa­
tients' compliance. But the incidence of allergic skin re­
action is considered to be a disadvantage of the applica­
tion of transdermal therapeutic systems. 
In 1985 Vlasses et al 5 was the first to evaluate the 
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serum concentration and the /?-blockade of transder-
mally applied timolol in normotensives. In our study we 
tested for the first time the effectiveness of the blood 
pressure lowering effect of a transdermal ^-blockade 
with mepindolol in essential hypertensives and the ef­
fect on 24-hour blood pressure profiles in essential hy­
pertensives. 
METHODS AND MATERIALS 
Ten patients with essential hypertension from our out­
patient department were included in this pilot study. 
The mean age was 37.7 ± 11.2 years; there were 6 
males, and 4 females; the average blood pressure was Ρ 
systolic 160.1 ± 6.1 mm Hg and Ń diastolic 95.8 ± 8.3 
mm Hg. All subjects were deemed to be in good health 
on the basis of medical history, physical examination, 
and laboratory screening evaluation. The subjects con­
sumed no other medication from 4 weeks prior and 
throughout the duration of the study. 
An ambulatory 24-hour blood pressure registration, 
an ECG, a complete blood chemistry, and a clinical ex­
amination were performed in each patient before ther­
apy and after 1 and 3 weeks of therapy. Before starting 
the study patient consent was obtained, and they were 
informed about the new treatment with the transdermal 
therapeutic system. Furthermore the local Institutional 
Review Boards were informed. Each patient taking part 
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FIGURE 1. Twenty-four-hour blood 
pressure profiles and heart rates before 
therapy (open figures) and after 3 
weeks of transdermal mepindolol ther­
apy (closed figures) (bars represent 
main value ± SD). 
in the trial received at the same time in a 24-hour-time-
course the transdermal therapeutic system, which con­
tained 20 mg mepindolol sulfate, a non-selective â -
adreno-receptive blocking agent. In this new 
therapeutic system, the adhesive area and the effective 
component of the occlusive matrix-system were sepa­
rated. All patches were self-adhesive and measured 9.8 
cm 2 in size. A microporous control membrane guaran­
teed a release of 20 mg Mepidolol in 24 hours. Systemic 
side effects were evaluated at each visit by an analogue 
scale. Cutaneous compatibility was constantly exam­
ined by a dermatologist. Withdrawal from the study was 
performed because of intolerable side effects or skin 
incompatibilities. Statistical analysis was performed by 
Students' t test. Values are given as means ± SD. 
RESULTS 
The patients of the study group approved this new ther­
apeutic system. One patient had to withdraw because of 
local skin irritation after 10 days of treatment. After 1 
week of therapy, 10 of the patients showed a good blood 
pressure response, the blood pressure lowering effect 
even improved after 3 weeks of therapy (Figure 1). 
After 1 week, the systolic blood pressure decreased to 
136.8 ± 7.2 mm Hg (P < 0.05) and diastolic to 84.3 ± 
5.0 mm Hg (P < 0.05); after 3 weeks the systolic blood 
pressure was 131.2 ± 2.1 mm Hg and the diastolic 
blood pressure was 82.1 ± 7.9 mm Hg. The heart rate 
decreased from 76.7 ± 5 . 1 beats/min to 72.2 ± 4 . 1 
beats/min after 1 week and after 3 weeks to 69.2 ± 5.2 
beats/min (NS). There was no significant change of the 
evaluated chemistry data. 
DISCUSSION 
The usage of ^-adrenergic blocking agents has increased 
greatly in the last 10 years. Therefore a long-lasting and 
well-tolerated transdermal ^-blocker could facilitate 
drug administration and increase the patients' compli­
ance. The results of this first trial with transdermal me­
pindolol in essential hypertensives document a good 
blood pressure lowering effect of this new transdermal 
therapeutic system, which was in the same range as it is 
expected for oral administration. 
Reports of Vlasses et al 5 in a normotensive group 
showed that measurable serum concentrations of a ί -
blocking agent in the therapeutic range can be achieved 
by a transdermal delivery. Furthermore it can be dem­
onstrated that the characteristic blood pressure devia­
tions in the morning and afternoon are significantly re­
duced after therapy.6 
The results of this initial study are encouraging. Fur­
ther studies are warranted to identify the effects asso­
ciated with longer periods of application and whether or 
not skin irritation might be a limiting factor in a pro­
longed exposure. Furthermore a controlled transdermal 
ί-blocker study versus oral ί-blocker administration in 
hypertensive patients is necessary before this new ther­
apeutic system is finally introduced to antihypertensive 
treatment. 
REFERENCES 
1. Sewing K-Fr: Transdermale Medikamentenapplikation. 
Dtsch Med Wschr 1983;107:603-604. 
2. Cronin CM, Sallan StE, Wolfe C: Transdermal scopola­
mine in motion sickness. Pharmacother 1982;2:29-31. 
3. Lowenstein J: Clonidine. Ann Intern Med 1980;92:74. 
4. Groth H, Vetter H, Kniesel J, Foerster Ε, Vetter W: Trans­
dermal Clonidine application: long-term results in essen­
tial hypertension. Klin Wochenschr 1984;62:925-930. 
5. Vlasses PH, Riberion LGT, Rotmensch HH: Initial evalua­
tion of transdermal timolol: serum concentrations and ß -
blocker. J Cardiovasc Pharmacol 1985;7:245-250. 
6. Spieker C, Vetter W, et al: Transdermal Betablocker: Wir­
kung auf 24-stunden-Blutdruckprofile bei Hypertoniepa­
tienten. Schw Rundschau Med (Praxis) 76, Nr. 17, 1987. 
